Agilon Health, Inc. — Form 8-K Summary
Reporting period and event: The report was filed April 19, 2021, concerning events beginning April 14, 2021. The principal event was the closing of agilon health’s initial public offering.
Business and Capital Markets Context
Agilon health priced its IPO at $23.00 per share under its Form S-1 registration statement. The underwriters exercised their option to purchase an additional 6,990,000 shares, and the company completed the sale of an aggregate of 53,590,000 shares on April 19, 2021. The offering implies approximately $1.23 billion of gross proceeds before underwriting discounts, commissions, and offering expenses.
The company’s common stock trades on the New York Stock Exchange under the symbol AGL.
Financial Metrics and Liquidity
- The filing does not provide revenue, net income, operating margins, cash flow, debt, cash balances, or other operating financial metrics.
- IPO proceeds are expected to increase the company’s liquidity, but the filing does not state the final net proceeds or their specific allocation.
Material Changes and Corporate Actions
- In connection with the IPO, agilon health entered into a Registration Rights Agreement and a Stockholders Agreement with CD&R Vector Holdings, L.P.
- The consulting agreement with Clayton, Dubilier & Rice LLC was terminated pursuant to a related Termination Agreement.
- The company’s Amended and Restated Certificate of Incorporation and Amended and Restated By-laws became effective on April 16, 2021.
- The IPO closing press release was filed as an exhibit.
Outlook, Risks, and Unusual Items
The filing provides no earnings guidance, operating outlook, or updated risk disclosures. Investors should note the potential effects of the IPO on ownership, governance, registration rights, and relationships with CD&R Vector Holdings. The filing does not describe the detailed terms of these agreements beyond incorporating the related exhibits and registration-statement descriptions.
Key Facts to Verify
- Final net IPO proceeds after underwriting discounts and offering expenses.
- Use of IPO proceeds and resulting cash and liquidity position.
- Ownership percentages and governance rights under the Stockholders Agreement.
- Registration rights and potential future share sales under the Registration Rights Agreement.
- Terms and financial consequences of terminating the Clayton, Dubilier & Rice consulting agreement.
- Underlying financial performance and operating outlook, which are not provided in this Form 8-K.